Low expression of miR-1469 predicts disease progression and unfavorable post‑surgical clinical outcomes in patients with esophageal squamous cell cancer

  • Authors:
    • Jin Liu
    • Chuifang Wang
    • Xiangyan Liu
    • Yu Wang
    • Haibo Liu
    • Guohua Ren
    • Liangming Zhu
    • Zhigang Sun
    • Zhitao Chen
  • View Affiliations

  • Published online on: March 30, 2017     https://doi.org/10.3892/ol.2017.5957
  • Pages: 4469-4474
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Recent studies have demonstrated that deregulated microRNA (miRNA/miR) expression has a profound impact on biological and pathological processes; abnormal miR-1469 expression was detected in several human malignancies. In the present study, the clinicopathological and prognostic significance of miR‑1469 was assessed in 129 patients with esophageal squamous cell cancer (ESCC) who successfully underwent esophagectomy and esophagogastrostomy. Low miR‑1469 expression was identified to be significantly associated with tumor invasion depth (P=0.026), lymph node metastasis status (P<0.001) and pathological tumor stage (P<0.001). Survival analysis demonstrated that patients with low miR‑1469 expression had significantly poorer disease‑free survival (DFS) (18.2 vs. 43.2%; P=0.004) and overall survival (29.1 vs. 47.3%; P=0.029) 5 years following surgery compared with patients with high miR‑1469 expression. Univariate survival analysis demonstrated that low miR‑1469 expression significantly predicted unfavorable 5‑year DFS among patients with N1‑3 disease (7.1 vs. 31.8%; P=0.043). The results from the present study indicate that miR‑1469 expression could be used in the clinic to predict ESCC progression and prognosis. This will aid in the identification of high‑risk patients with ESCC that require more aggressive therapeutic interventions.

Introduction

Esophageal cancer occurs worldwide, and Eastern Asia has one of the highest incidence rates (1). Esophageal squamous cell cancer (ESCC), the predominant histological type, is the most common subtype of esophageal cancer in Eastern Asia, including China (2). Owing to the aggressive invasion, early metastasis, therapeutic resistance and other malignant biological behaviors of ESCC, the prognosis is poor, despite numerous efforts to develop effective therapeutic interventions, such as early detection, advanced surgical techniques and chemoradiotherapy (3). Therefore, it is important to identify novel molecular biomarkers to allow for the identification of high-risk patients that require prompt and tailored treatment (4). However, efforts to identify specific molecules associated with ESCC progression and prognosis have thus far been unsuccessful (5), to the best of our knowledge.

MicroRNAs (miRNAs/miRs) are small, endogenous non-coding RNAs that are highly conserved across a variety of eukaryotic species (6,7). Since the first report to highlight the roles of miRNAs in chronic lymphocytic leukemia (8), several studies have demonstrated that the deregulation of miRNA expression has a profound impact on human biological and pathological processes through a number of molecular mechanisms (911). Abnormal miR-1469 expression has been reported in several human malignancies (1215). However, the role miR-1469 serves in ESCC has not yet been reported, to the best of our knowledge. In the present study, the expression of miR-1469 in ESCC tissues, and the value of miR-1469 in predicting disease progression, relapse and prognosis, was investigated.

Materials and methods

Patients and follow-up

The present study recruited patients who underwent the surgical resection of a primary ESCC between September 2009 and June 2010 at Shandong Provincial Hospital Affiliated to Shandong University and Jinan Central Hospital Affiliated to Shandong University (Jinan, China). The 129 patients included in the present study had not received preoperative chemotherapy and/or radiotherapy, had undergone R0 resection and esophagogastrostomy without perioperative death, and also had complete clinicopathological and follow-up data. Clinicopathological data for the recruited patients is illustrated in Table I.

Table I.

Association between of miR-1469 expression and the clinicopathological characteristics of patients with esophageal squamous cell cancer.

Table I.

Association between of miR-1469 expression and the clinicopathological characteristics of patients with esophageal squamous cell cancer.

miR-1469 expression (no. of patients)

Clinicopathological characteristicNo. of patientsLowHighP-valuea
Age (years) 0.829
  <60532231
  ≥60763343
Gender 0.124
  Male1024755
  Female27  819
Tumor length (cm) 0.224
  <5853352
  ≥5442222
Tumor differentiation 0.082
  High31  823
  Moderate632934
  Low351817
Tumor invasion depth 0.026
  T123  617
  T2401327
  T3512625
  T41510  5
Lymph node metastasis stage <0.001
  N0651352
  N1291910
  N22314  9
  N312  9  3
Pathological tumor stage <0.001
  I18  315
  II581741
  III533518

a χ2 test.

Tumor samples were collected immediately following surgical resection, snap-frozen in liquid nitrogen and then stored at −80°C until required for the extraction of total RNA. The histopathologic diagnosis of ESCC was verified based on sections stained with hematoxylin and eosin, according to the classification system of the World Health Organization (16). Tumor-node-metastasis (TNM) staging was determined based on the 7th classification guidelines of the American Joint Committee on Cancer (17). Written informed consent was obtained from each patient, and the study design was approved by the Institutional Review Boards of Shandong Provincial Hospital Affiliated to Shandong University and Jinan Central Hospital Affiliated to Shandong University, (Shandong, China).

All patients were followed up at 3–6 month intervals, using a number of medical procedures, including physical examination, upper gastrointestinal barium meal examination, ultrasound examination, computed tomography and gastroscopy, until patient mortality (all causes) or the end of the study period (June 2015). The median follow-up period was 35 months, with a range of 6–68 months.

Real-time quantitative reverse transcription-polymerase chain reaction (RT-qPCR)

Total RNA was extracted from each frozen tissue sample using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's instructions. The purity and concentration of all RNA samples was measured using a spectrophotometer (NanoDrop; Thermo Fisher Scientific, Wilmington, DE, USA).

cDNA was reverse transcribed from 100 ng RNA using SYBR® Premix Ex Taq (Takara Biotechnology Co., Ltd., Dailan, China) in a final volume of 20 µl, according to the manufacturer's instructions. The RT conditions used are as follows: 37°C for 60 min, 85°C for 5 sec and 4°C for 60 min. Subsequently, quantification of miR-1469 expression was performed by RT-qPCR using SYBR® Premix Ex Taq II on a MX3000P instrument (Agilent Technologies, Inc., Santa Clara, CA, USA). The qPCR consisted of 2 µl (10 ng) cDNA, 12.5 µl SYBR Premix Ex Taq II, 0.5 µl Dye II, 2 µl 5 µM forward primer, 1 µl 10 µM Uni-miR RT-qPCR primer and 7 µl of ddH2O. The qPCR conditions used were as follows: 95°C for 30 sec, 45 cycles of 95°C for 5 sec and 57°C for 34 sec. The sequences of the primers are as follows: miR-1469 forward, 5′-GGGCTGAGCTGAAGCAGTG-3′, and reverse, 5′-CAGTGCGTGTCGTGGAGT-3′, U6 forward, 5′-GCTTCGGCAGCACATATACTAAAAT-3′, and reverse primer, 5′-CGCTTCACGAATTTGCGTGTCAT-3′. The small nuclear RNA U6, which is highly conserved and universally expressed, was used as the endogenous reference. Relative changes of miR-1469 expression were calculated using the comparative threshold cycle (2−ΔΔCq) method (18) and normalized to U6 expression. All RT-qPCR reactions were performed in triplicate. High or low miR-1469 expression was defined based on the median expression cut-off value, which was calculated separately for each cohort (19).

Statistical analysis

All statistical analyses were performed using SPSS software (version 18.0; SPSS Inc., Chicago, IL, USA). A χ2 test was used to determine the association between miR-1469 expression levels and clinicopathological characteristics. The Kaplan-Meier method was used to calculate survival curves and the log-rank test for the univariate analysis was performed to determine the statistical significance of differences between the survival curves of patient subgroups. Disease-free survival (DFS) was calculated from the date of surgery to the date of tumor recurrence or the last follow-up. Overall survival (OS) was calculated from the date of surgery to the date of death or the last follow-up. Multivariate analysis was performed using the Cox proportional hazards regression model to identify independent prognostic factors for predicting survival. P<0.05 was considered to indicate a statistically significant difference.

Results

Association between miR-1469 expression and clinicopathological characteristics

The expression levels of miR-1469 in each sample were determined by RT-qPCR, and compared with clinicopathological characteristics using a χ2 test (Table I). Low miR-1469 expression was significantly associated with tumor invasion depth (26.1% in T1, 32.5% in T2, 51.0% in T3 and 66.7% in T4 cases; P=0.026), lymph node metastases (20.0% in N0, 65.5% in N1, 60.9% in N2, and 75.0% in N3 cases; P<0.001) and pathological stage (16.7% in I, 29.3% in II and 66.0% in III cases; P<0.001). However, no association was identified between miR-1469 expression and patient age or gender. Additionally, no association was identified between miR-1469 expression and tumor length or differentiation.

Association between miR-1469 expression and tumor relapse

The location and time of tumor relapse was recorded during the follow-up period. A total of 87 patients suffered tumor relapse and the 5-year DFS rate was 32.6%. Of the 87 patients, 45 (51.7%) had low tumor miR-1469 expression and 42 cases (48.3%) had high tumor miR-1469 expression (P=0.003; data not shown). A univariate analysis demonstrated that the 5-year DFS was significantly decreased for patients with low tumor miR-1469 expression than for those with high tumor miR-1469 expression (18.2 vs. 43.2%; P=0.004; Fig. 1A). In addition, multivariate analysis demonstrated that only lymph node metastasis status retained its significance as an independent predictor for unfavorable DFS [P=0.031; 95% confidence interval (CI), 1.035–2.089; Table II].

Table II.

Results of univariate and multivariate analyses for the association between clinicopathological characteristics and survival in patients with esophageal squamous cell cancer.

Table II.

Results of univariate and multivariate analyses for the association between clinicopathological characteristics and survival in patients with esophageal squamous cell cancer.

Disease-free survivalOverall survival


Multivariate analysis Multivariate analysis


Clinicopathological characteristicUnivariate analysis P-valueP-value95.0% CIUnivariate analysis P-valueP-value95.0% CI
Age0.5980.3520.516–1.5160.8090.5390.534–1.534
Gender0.8020.7610.636–1.6360.8470.7830.518–1.518
Tumor length0.6650.9470.614–1.6140.6170.9350.621–1.621
Tumor differentiation0.0950.5120.803–1.8030.2800.8120.741–1.741
Tumor invasion depth0.0330.5120.785–1.7850.0090.3610.815–1.815
Lymph node metastasis stage<0.0010.0311.035–2.035<0.0010.0201.070–2.070
Pathological tumor stage<0.0010.7420.552–2.552<0.0010.5820.582–2.582
miR-1469 expression0.0040.3220.488–1.4880.0290.9770.595–1.595

[i] CI, confidence interval.

The predictive significance of miR-1469 expression in selective patient subgroups was stratified according to lymph node metastasis status and pathological stage, respectively. Univariate analysis demonstrated that the 5-year DFS of patients with low tumor miR-1469 expression was significantly lower compared with that of the remaining cases with high miR-1469 expression among N1-3 patients (7.1 vs. 31.8%; P=0.043; Fig. 1B). However, this was not the case for patients with N0 (53.8 vs. 48.1%; P=0.751), pathological stage I–II (40.0 vs. 48.2%; P=0.582) or pathological stage III (5.7 vs. 27.8%; P=0.128) tumors with low miR-1469 tumor expression compared with the corresponding groups with high miR-1469 tumor expression (data not shown).

Association between miR-1469 expression and prognosis

Of the 129 patients, 78 succumbed to mortality within the follow-up period and the 5-year OS rate was 39.5% (data not shown). Univariate analysis revealed that low miR-1469 expression was associated with an unfavorable 5-year OS compared with high miR-1469 expression (29.1 vs. 47.3%; P=0.029; Fig. 1C). Multivariate analysis revealed that only lymph node metastasis retained its significance as an independent predictor for unfavorable OS (P=0.020; 95% CI, 1.070–2.202; Table II).

A further stratified survival analysis demonstrated that miR-1469 expression was not associated with an unfavorable 5-year OS for subgroups of patients grouped according to lymph node metastasis status (N0, 69.2 vs. 51.9%; P=0.353; N1-3, 16.7 vs. 36.4%; P=0.145) and pathological stage (I–II, 65.0 vs. 53.6%, P=0.566; III, 8.6 vs. 27.8%; P=0.223) (data not shown).

Discussion

Esophageal cancer is one of the most aggressive and deadly malignancies of the digestive tract, with patients typically presenting with bulky tumors and metastasis at the time of clinical diagnosis. The prognosis of patients with esophageal cancer remains poor and only a subset of patients respond well to treatment (4,20). The current TNM classification cannot accurately predict clinical outcome for patients with ESCC (21), even for patients with identical clinicopathological risk factors. Clearly distinguishing between subgroups of patients who have a high or low risk of relapse, treatment resistance and metastasis remains a challenge (22), therefore there is an urgent need to identify biomarkers that can be used to identify patients that require more aggressive postoperative treatment.

miRNAs are deregulated in numerous human cancers (23,24). Previous studies have demonstrated that miRNAs are reliable and cost-effective biomarkers that can be utilized in the diagnosis and assessment of the progression, therapeutic response and prognosis of a wide spectrum of malignant tumors, including esophageal cancer (7,2527). A better understanding of the miRNAs associated with particular cancers would provide valuable insights for treatment. Previous studies have demonstrated that miR-1469 may function as an oncogene (12,13) or a tumor suppressor gene (14,15) in malignant tumors originating from different tissues. However, to the best of our knowledge, the effects of miR-1469 expression on the progression and clinical outcome of human ESCC has not yet been reported.

In the present study, the expression of miR-1469 in tumor samples from 129 ESCC patients was analyzed by RT-qPCR and compared with clinicopathological characteristic and survival data. Low miR-1469 expression was significantly associated with invasion depth, lymph node metastasis status and pathological stage, suggesting that miR-1469 acts as a tumor suppressor. Low expression of miR-1469 was significantly associated with a poor prognosis; a univariate analysis revealed a correlation between low miR-1469 expression and a poor 5-year DFS and OS. A multivariate analysis demonstrated that only lymph node metastasis status could predict tumor relapse and prognosis independently of other clinicopathological parameters.

To explore whether miR-1469 expression levels could be employed as a predictor to improve the current risk stratification for ESCC based on the conventional staging system, a further stratified survival analysis split by lymph node metastasis status and pathological stage was performed. The results demonstrated that low miR-1469 expression only significantly predicted an unfavorable 5-year DFS among the subgroup of patients with N1-3 disease. Although statistically significant differences were not detected, low miR-1469 expression was associated with a poorer DFS and OS in the subgroup of patients with pathologic stage III disease. Therefore, the data from the present study indicate that miR-1469 expression can predict the clinical outcome of ESCC, particularly in patients with advanced disease. Measuring miR-1469 expression levels in patients with ESCC may allow clinicians to more accurately identify high-risk patients who would benefit from more aggressive therapeutic interventions.

Previous studies have identified an association between dysregulated miRNA expression and cancer diagnosis (28,29). In addition, it has been demonstrated that miRNAs modulate numerous signaling pathways and regulate the expression of thousands of genes (7,30). The current gold standard of cancer diagnosis is a pathological diagnosis, due to the heterogeneous nature of tumors. Future studies will need to be performed to ascertain whether miR-1469 can be reliably used as biomarker for the diagnosis of ESCC.

In conclusion, to the best of our knowledge, the data in the present study provides the first evidence for the role of miR-1469 in predicting disease progression and post-surgical clinical outcomes in patients with ESCC. These data are consistent with previous reports evaluating the tumor suppressor roles of miR-1469 in human cancer (14,15). However, multicenter and large-scale studies are required to verify this data prior to the clinical application of miR-1469, in addition to in vitro and in vivo functional studies to identify the target genes and signaling pathways of miR-1469. The results of these studies may allow for the identification and selection of high-risk patients that would benefit from specific treatments following surgery, therefore improving clinical outcomes.

Glossary

Abbreviations

Abbreviations:

ESCC

esophageal squamous cell cancer

TNM

tumor-node-metastasis

DFS

disease-free survival

OS

overall survival

References

1 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Chen W, He Y, Zheng R, Zhang S, Zeng H, Zou X and He J: Esophageal cancer incidence and mortality in China, 2009. J Thorac Dis. 5:19–26. 2013.PubMed/NCBI

3 

Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013. View Article : Google Scholar : PubMed/NCBI

4 

Kim T, Grobmyer SR, Smith R, Ben-David K, Ang D, Vogel SB and Hochwald SN: Esophageal cancer-the five year survivors. J Surg Oncol. 103:179–183. 2011. View Article : Google Scholar : PubMed/NCBI

5 

Hong L, Han Y, Zhang H and Fan D: Prognostic markers in esophageal cancer: From basic research to clinical use. Expert Rev Gastroenterol Hepatol. 9:887–889. 2015. View Article : Google Scholar : PubMed/NCBI

6 

Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI

7 

Naidu S, Magee P and Garofalo M: MiRNA-based therapeutic intervention of cancer. J Hematol Oncol. 8:682015. View Article : Google Scholar : PubMed/NCBI

8 

Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI

9 

Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009. View Article : Google Scholar : PubMed/NCBI

10 

Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Ohtsuka M, Ling H, Doki Y, Mori M and Calin GA: MicroRNA processing and human cancer. J Clin Med. 4:1651–1667. 2015. View Article : Google Scholar : PubMed/NCBI

12 

Fix LN, Shah M, Efferth T, Farwell MA and Zhang B: MicroRNA expression profile of MCF-7 human breast cancer cells and the effect of green tea polyphenon-60. Cancer Genomics Proteomics. 7:261–277. 2010.PubMed/NCBI

13 

White NM, Khella HW, Grigull J, Adzovic S, Youssef YM, Honey RJ, Stewart R, Pace KT, Bjarnason GA, Jewett MA, et al: miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer. 105:1741–1749. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Yang B, Jing C, Wang J, Guo X, Chen Y, Xu R, Peng L, Liu J and Li L: Identification of microRNAs associated with lymphangiogenesis in human gastric cancer. Clin Transl Oncol. 16:374–379. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Xu C, Zhang L, Li H, Liu Z, Duan L and Lu C: MiRNA-1469 promotes lung cancer cells apoptosis through targeting STAT5a. Am J Cancer Res. 5:1180–1189. 2015.PubMed/NCBI

16 

Hamilton SR and Aaltonen LA: Pathology and genetics of tumours of the digestive system, World Health Organization classification of tumours. IARC Press; Lyon: pp. 10–25. 2000

17 

Edge SF, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: Esophagus and esophagogastric junctionAJCC Cancer Staging Manual. 7th edition. Springer; New York, NY: pp. 103–111. 2010

18 

Zhou H, Tang K, Xiao H, Zeng J, Guan W, Guo X, Xu H and Ye Z: A panel of eight-miRNA signature as a potential biomarker for predicting survival in bladder cancer. J Exp Clin Cancer Res. 34:532015. View Article : Google Scholar : PubMed/NCBI

19 

Mathé EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, et al: MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: Associations with survival. Clin Cancer Res. 15:6192–6200. 2009. View Article : Google Scholar : PubMed/NCBI

20 

Enzinger PC and Mayer RJ: Esophageal Cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI

21 

Li SH, Tian H, Yue WM, Li L, Gao C, Li WJ, Hu WS and Hao B: Metastasis-associated protein 1 nuclear expression is closely associated with tumor progression and angiogenesis in patients with esophageal squamous cell cancer. World J Surg. 36:623–631. 2012. View Article : Google Scholar : PubMed/NCBI

22 

Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X, Li B, Meng X, Ma X, Luo M, et al: Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res. 68:26–33. 2008. View Article : Google Scholar : PubMed/NCBI

23 

Pipan V, Zorc M and Kunej T: MicroRNA polymorphisms in cancer: A literature analysis. Cancers (Basel). 7:1806–1814. 2015. View Article : Google Scholar : PubMed/NCBI

24 

Lin S and Gregory RI: MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI

25 

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI

26 

Garzon R, Calin GA and Croce CM: MicroRNAs in Cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI

27 

Raza U, Zhang JD and Sahin O: MicroRNAs: Master regulators of drug resistance, stemness, and metastasis. J Mol Med (Berl). 92:321–336. 2014. View Article : Google Scholar : PubMed/NCBI

28 

Tricoli JV and Jacobson JW: MicroRNA: Potential for cancer detection, diagnosis, and prognosis. Cancer Res. 67:4553–4555. 2007. View Article : Google Scholar : PubMed/NCBI

29 

Kosaka N, Iguchi H and Ochiya T: Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 101:2087–2092. 2010. View Article : Google Scholar : PubMed/NCBI

30 

Ye Y, Wang KK, Gu J, Yang H, Lin J, Ajani JA and Wu X: Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila). 1:460–469. 2008. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June-2017
Volume 13 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu J, Wang C, Liu X, Wang Y, Liu H, Ren G, Zhu L, Sun Z and Chen Z: Low expression of miR-1469 predicts disease progression and unfavorable post‑surgical clinical outcomes in patients with esophageal squamous cell cancer. Oncol Lett 13: 4469-4474, 2017
APA
Liu, J., Wang, C., Liu, X., Wang, Y., Liu, H., Ren, G. ... Chen, Z. (2017). Low expression of miR-1469 predicts disease progression and unfavorable post‑surgical clinical outcomes in patients with esophageal squamous cell cancer. Oncology Letters, 13, 4469-4474. https://doi.org/10.3892/ol.2017.5957
MLA
Liu, J., Wang, C., Liu, X., Wang, Y., Liu, H., Ren, G., Zhu, L., Sun, Z., Chen, Z."Low expression of miR-1469 predicts disease progression and unfavorable post‑surgical clinical outcomes in patients with esophageal squamous cell cancer". Oncology Letters 13.6 (2017): 4469-4474.
Chicago
Liu, J., Wang, C., Liu, X., Wang, Y., Liu, H., Ren, G., Zhu, L., Sun, Z., Chen, Z."Low expression of miR-1469 predicts disease progression and unfavorable post‑surgical clinical outcomes in patients with esophageal squamous cell cancer". Oncology Letters 13, no. 6 (2017): 4469-4474. https://doi.org/10.3892/ol.2017.5957